Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)

Send us Fan Mail

 On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including those on Medicare and Medicaid. If you are a life sciences executive or legal counsel, this is the compliance roadmap you’ve been waiting for. 

Support the show

www.kulkarnilawfirm.com